Venus Remedies Limited — Board Meeting, 01-08-2025: Outcome of Board Meeting

Venus Remedies' Board has approved consolidated financial results for Q1 FY26. Revenue from operations climbed to ₹131.90 Cr (from ₹108.61 Cr YoY), with Net Profit jumping significantly to ₹9.60 Cr (vs ₹1.22 Cr). EPS robustly increased to ₹7.18. The company noted its German subsidiary, Venus Pharma GmbH, has a negative net worth of ₹2.95 Cr, but expects stabilization by FY26 end with holding company support. A strategic investment of ₹28.60 Cr in the subsidiary is pending share allotment due to German laws.